Sunepitron

Sunepitron (CP-93,393) is a combined 5-HT1A receptor agonist and α2-adrenergic receptor antagonist. It was previously under development by Pfizer for the treatment of depression and anxiety. It made it to phase III clinical trials before being discontinued.

Synthesis


G.N. Bright, K.A. Desai, (1992).